File(s) not publicly available
The LORIS trial: addressing overtreatment of ductal carcinoma in situ
journal contribution
posted on 2023-06-08, 19:17 authored by A Francis, Lesley FallowfieldLesley Fallowfield, D ReaAn unforeseen consequence of the introduction of mammographic breast screening has been the marked increase in the number of women diagnosed with ductal carcinoma in situ (DCIS) [1,2]. In 2009–2010, 2830 women were diagnosed with in situ carcinoma through the National Health Service Breast Screening Programme (NHSBSP) [3]. Screen-detected DCIS now accounts for 20% of ‘cancers’ identified through breast screening. However, the intent of breast screening programmes was to detect early invasive cancer, not to identify DCIS.
History
Publication status
- Published
Journal
Clinical OncologyISSN
0936-6555Publisher
ElsevierExternal DOI
Issue
1Volume
27Page range
6-8Department affiliated with
- Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2014-12-15Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC